Brought to you by 
Teva, Alpharma sign deal to sell gabapentin
09 Dec 2020
Executive Summary
Generics companies Teva Pharmaceutical Industries and Alpharma will work together on the launch and marketing of capsule and tablet formulations of gabapentin, the generic version of Pfizer's anticonvulsant Neurontin.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva, Alpharma sign deal to sell gabapentin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice